Evidence map›Paper›PMID 38252376›Full record

ArticleDermatology and therapy2024

Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.

April W Armstrong, Sayeli Jayade, Sanika Rege, Namita Joshi, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Dipen Patel, Lauren Seigel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.The Journal of clinical and aesthetic dermatology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

April W ArmstrongDivision of Dermatology, David Geffen Department of Medicine, University of California Los Angeles, 200 Medical Plaza, Suite 450, Los Angeles, CA, 90095, USA. armstrongpublication@gmail.com.ORCID http://orcid.org/0000-0003-0064-8707
Sayeli JayadeOPEN Health Evidence & Access, Bethesda, MD, USA.
Sanika RegeOPEN Health Evidence & Access, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2405-0147
Namita JoshiOPEN Health Evidence & Access, Bethesda, MD, USA.
Vardhaman PatelBristol Myers Squibb, Princeton, NJ, USA.ORCID http://orcid.org/0000-0002-3636-3423
Samaneh KaliraiBristol Myers Squibb, Princeton, NJ, USA.
Daniel WolinRTI Health Solutions, Research Triangle Park, NC, USA.ORCID http://orcid.org/0009-0004-4437-8424
Kimberly BoyleRTI Health Solutions, Research Triangle Park, NC, USA.
Dipen PatelOPEN Health Evidence & Access, Bethesda, MD, USA.
Lauren SeigelBristol Myers Squibb, Princeton, NJ, USA.ORCID http://orcid.org/0000-0001-5977-3065
Access to Wholistic and Productive Living Institute · USBristol-Myers Squibb (United States) · USRTI Health Solutions · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile multiple treatments are available for moderate to severe psoriasis, patient preferences are rarely systematically studied. This study aims to identify factors associated with choice of a new once-daily oral psoriasis treatment, elicit patient views on treatment characteristics, and rank treatment characteristics by importance.

methodsThis noninterventional, cross-sectional survey study, conducted from December 2021 to June 2022, recruited US adults with moderate to severe psoriasis. Demographics, clinical characteristics, and perspectives on psoriasis treatment were collected. Factors associated with the choice of a new oral treatment were identified using multivariable logistic regression analysis. Treatment characteristics and reasons for treatment choice were ranked using bivariate comparisons.

resultsThe study included 882 participants [mean (standard deviation; SD) age, 45.7 (12.8) years; female, 67.7%; White, 74.9%]; 92.7% were currently receiving treatment [mean (SD) duration, 2.9 (4.8) years]. Half of participants rated their psoriasis symptoms over the past week as mild, very mild, or nonexistent; 36.5% as moderate; and 12.7% as severe or very severe. Most (66.5%) indicated willingness to start a new oral treatment; 65.0% indicated that the new oral treatment would cause less anxiety than injections/infusions. Participants were significantly more likely to start the new oral treatment if they were currently receiving a tumor necrosis factor inhibitor [odds ratio (OR): 2.1, 95% confidence interval (CI): 1.4-3.1] or ustekinumab (OR: 2.7, 95% CI: 1.6-5.0) versus apremilast (P < 0.001) or if they reported mild (OR: 3.2, 95% CI: 2.0-4.9), moderate (OR: 5.0, 95% CI: 3.1-8.2), or severe (OR: 7.6, 95% CI: 3.9-15.0) psoriasis symptoms compared with those who reported no symptoms in the past week (P < 0.001).

conclusionMost participants indicated willingness to start a new once-daily oral treatment, viewing it as less anxiety provoking than injections/infusions. Current treatment and psoriasis severity affected participants' willingness to start a new oral treatment.

Indexed as

ApremilastBiologicsDecision makingPhototherapyPsoriasis

Identifiers

PMID38252376
PMCPMC10891029
OpenAlexW4391106033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.